ARTICLE | Deals
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
February 6, 2024 1:30 AM UTC
Novo Nordisk’s $11 billion acquisition of three fill-finish sites on two continents represents a giant step toward alleviating supply concerns around fast-selling obesity drug Wegovy semaglutide.
The two-step process began with the acquisition by Novo Holdings A/S of Catalent Inc. (NYSE:CTLT) for $63.50 per share, suggesting an enterprise value of $16.5 billion. Then, Novo Holdings sold the three sites — in Belgium, Italy and Indiana — to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651353/deals-roundup-novo-boosts-obesity-manufacturing-with-catalent-buy